Jonathan Licht/X
Oct 9, 2024, 16:24
Jonathan Licht: How KDM6A controls MHC-I and II expression in multiple myeloma cells
Jonathan Licht, Director of the UF Health Cancer Center, shared a post on X:
“Our paper on how tumor suppressor KDM6A controls MHC-I and II expression in multiple myeloma cells is out in print in Blood Journal.
KDM6A loss can be ameliorated by treatment of cells with an HDAC3 inhibitor, restoring MHC expression.”
KDM6A controls immunogenicity in MM
Authors: Jerome Moreaux.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 17:58
May 29, 2025, 17:45
May 29, 2025, 17:39
May 29, 2025, 17:28